Fifth Third Bancorp (Cincinnati OH) (FITB) Pops 6.67% for February 15

Equities Staff |

One of the S&P 500’s big winners for Monday February 15 was Fifth Third Bancorp (Cincinnati OH) (FITB) as the company’s stock climbed 6.67% to $14.87 on volume of 10.6 million shares.

The stock opened at $14.26 and saw an intraday low of $14.21 and an intraday high of $14.89. All told, the day saw a per-share gain of $0.93. The stock’s average daily volume of 9.49 million and 794.33 million shares outstanding. Fifth Third Bancorp (Cincinnati OH) now has a 50-day SMA is $18.01 and 200-day SMA is $19.47, and it has a 52-week high of $21.93 and a 52-week low of $13.84.

Fifth Third Bancorp along with its subsidiaries provides financial products and services such as checking, savings and money market accounts, and credit products such as credit cards, installment loans, mortgage loans and leases.

Based out of Cincinnati, OH, Fifth Third Bancorp (Cincinnati OH) has 18,311 employees and, after today’s trading, reached a market cap of $11.81 billion. The stock’s P/E Ratio is 6.9. Its P/S ratio is 1.57, P/B ratio is 0.82, and P/FCF ratio is 10.8.

For a complete fundamental analysis analysis of Fifth Third Bancorp (Cincinnati OH), check out’s Stock Valuation Analysis report for FITB. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…